消息显示,美国制药巨头百时美施贵宝(Bristol Myers Squibb)将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议,百时美施贵宝将向BioNTech支付15亿美元的预付款,整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流,还为其癌症研究领域的发展提供了强有力的支持。
BNT327是一种新一代免疫疗法,属于双特异性抗体类药物,主要针对PD-L1和VEGF-A这两种蛋白。目前,该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议,两家公司将共同开发和商业化BNT327,平分全球利润和亏损,共同承担开发和生产成本。
这一合作不仅有望加快BNT327的临床试验进程和上市时间,还可能扩大其潜在的适应症范围,为癌症患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.